Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism

Обзор

The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves social communication as well as the core and associated symptoms of ASD. The investigators will enroll 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known social and communication delays. Participation will last approximately 26 weeks, from screening visit to end of treatment.

Подробное описание

Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder with life-long consequences that affects young children during critical times in their development. ASD is defined by impairments in social-communication as well as the presence of restricted interests and repetitive behaviors. ASD is frequently associated with co-occurring language delays. Currently the only well-accepted treatment for core ASD symptoms is behavior therapy such as Applied Behavioral Analysis and Early Intensive Behavioral Intervention. There is no US Food and Drug Administration approved medical therapy that addresses core ASD symptoms or the pathophysiological processes that underlie ASD.

The primary aim of this study is to evaluate the effect of a liquid form of leucovorin calcium on social and communication impairments in very young children with ASD. Participants entered into the trial will have delayed language and moderate ASD symptoms. The investigators hypothesize that leucovorin calcium will significantly improve social communication as well as core and associated behavioral symptoms of ASD, and be well-tolerated with no significant adverse effects, in young children with ASD.

To assess whether the liquid form of leucovorin calcium is superior to placebo, the investigators will study 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known social and communication delays at baseline. Participants will be randomly assigned to receive active treatment or placebo for 12 weeks under double-blind conditions. At the end of 12 weeks, all participants will receive active treatment for 12 weeks. Language skills and social communication abilities will be measured at screening and after each treatment arm in order to determine if the supplement positively influences social communication. Additionally, the investigators will measure changes in neural pathways using either magnetoencephalography at Phoenix Children's Hospital or functional Near Infrared Spectroscopy at State University of New York, Downstate. While these measures will be considered exploratory, they will be important to begin to elucidate the neuronal mechanisms underlying leucovorin's impact.

Вмешательства

• Препарат Levoleucovorin Calcium
  Liquid leucovorin calcium dosed by weight
• Другое Placebo
  Placebo

Первичные конечные точки

• Evaluate the change in social communication symptoms [Срок оценки: Baseline, Week 6, Week 12, Week 24]

Вторичные конечные точки (12)

• Evaluate the safety and tolerability of L-leucovorin calcium in young children with ASD [Срок оценки: Screening, Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12, Week 16, Week 20, Week 24]
• Evaluate adverse effect symptoms in young children with ASD [Срок оценки: Screening, Week 12, Week 24]
• Evaluate the biologic safety of L-leucovorin calcium in young children with ASD [Срок оценки: Screening, Week 12, Week 24]
• Evaluate the safety of L-leucovorin calcium in young children with ASD on antiepileptic drugs [Срок оценки: Screening, Week 12, Week 24]
• Examine the change in measures of Expressive and Receptive Language [Срок оценки: Baseline, Week 12, Week 24]
• Evaluate the change in effects of autism symptoms on family members [Срок оценки: Baseline, Week 6, Week 12, Week 24]
• Evaluate the change in stereotypical autism symptoms [Срок оценки: Baseline, Week 6, Week 12, Week 24]
• Evaluate change in overall autism severity [Срок оценки: Baseline, Week 6, Week 12, Week 24]
• Evaluate change in specific autism symptom severity [Срок оценки: Baseline, Week 6, Week 12, Week 24]
• Evaluate the change in overall cognitive ability [Срок оценки: Baseline, Week 12, Week 24]
• Evaluate the change in adaptive functioning [Срок оценки: Baseline, Week 12, Week 24]
• Evaluate the overall change in core ASD symptoms of social communication [Срок оценки: Screening, Week 6, Week 12, Week 24]

Критерии участия

Критерии включения

• 1\. Autism Spectrum Disorder (diagnosed as Autistic Disorder on the ADOS-2 or the ADI-R).
• Between 2 years 6 months and 5 years 2 months of age at baseline
• Folate Receptor Alpha Autoantibody Positive status
• Language impairment (Ages and Stage Questionnaire between -1 and -3 SD for Language)
• English included in the languages in which the child is being raised
• Autism severity of moderate or higher (≥4) under the 7-item clinical global impression-severity scale. Moderate level of autism severity (4) is defined by the diagnosis of ASD with language impairment, so fulfilling #1 and #4 fulfills this requirement.
• Ability to maintain all ongoing complementary, dietary, traditional, and behavioral treatments constant for the study period
• Unchanged complementary, dietary, traditional, and behavioral treatments for two months prior to study entry
• Has at least 4 month old expressive language ability as assessed by the MSEL Expressive Language Scale (i.e., Parent answers "yes" to " Voluntary babbling (such as 'bu, bu, bu")" Question #7 on the MSEL Expressive Language Scale.
• Ability to attend to social stimulus and tolerate imaging procedures, as determined at the discretion of the investigator

Критерии исключения

• Known FRAA status by clinically validated test performed outside of research studies.
• Mineral or vitamin supplementation that exceeds the Tolerable Upper Daily Intake Levels set by the Institute of Medicine (See Table 6 below)
• Significant self-abusive or violent behavior or evidence of suicidal ideation, plan or behavior
• Severely affected children as defined by CGI-Severity Standard Score = 7 (Extremely Ill)
• Severe prematurity (<34 weeks gestation) as determined by medical history
• Current uncontrolled gastroesophageal reflux
• Current or history of liver or kidney disease as determined by medical history and safety labs
• Genetic syndromes
• Congenital brain malformations
• Epilepsy
• Any medical condition that the PI determines could jeopardize the safety of the study subject or compromise the integrity of the data
• Significant negative reaction (i.e. fainting, vomiting, etc.) as a result of a previous blood draw.
• Failure to thrive or Body Mass Index < 5%ile or <5%ile for weight (male <11.2kg; female <10.8kg by CDC 2000 growth charts) at the time of the study.
• Concurrent treatment with drug that would significantly interact with l-leucovorin such as specific chemotherapy agents, antimalarial and immune suppressive agents and select antibiotics (See Table 7 below).
• Allergy or Sensitivity to ingredients in the investigational product or placebo
• Evaluation with the MSEL or BOSCC within 3 months of entering the study
• Planned evaluation with the MSEL or BOSCC during the study
• Exclusion Criteria for the MEG recording include:

• Ferromagnetic implants, artificial joints, fixation hardware, dental work or shrapnel (additional screening will be completed to determine MRI eligibility)
• Ferromagnetic products attached to the body (including hair extensions)
• Head circumference greater than 60 cm
• A weight greater than 407 lbs. (185 kg)

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Четверное слепое

Основная цель

Лечение

Центры проведения

США · 2 центра

• Southwestern Research & Resource Center — Phoenix
• State University of New York, Downstate — Brooklyn

Публикации

• Frye RE, Rossignol DA, Scahill L, McDougle CJ, Huberman H, Quadros EV. Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder. Semin Pediatr Neurol. 2020 Oct;35:100835. doi: 10.1016/j.spen.2020.100835. Epub 2020 Jun 25. PMID 32892962
• Frye RE, Slattery JC, Quadros EV. Folate metabolism abnormalities in autism: potential biomarkers. Biomark Med. 2017 Aug;11(8):687-699. doi: 10.2217/bmm-2017-0109. Epub 2017 Aug 3. PMID 28770615
• Frye RE, Slattery J, Delhey L, Furgerson B, Strickland T, Tippett M, Sailey A, Wynne R, Rose S, Melnyk S, Jill James S, Sequeira JM, Quadros EV. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol Psychiatry. 2018 Feb;23(2):247-256. doi: 10.1038/mp.2016.168. Epub 2016 Oct 18. PMID 27752075
• Frye RE, Delhey L, Slattery J, Tippett M, Wynne R, Rose S, Kahler SG, Bennuri SC, Melnyk S, Sequeira JM, Quadros E. Blocking and Binding Folate Receptor Alpha Autoantibodies Identify Novel Autism Spectrum Disorder Subgroups. Front Neurosci. 2016 Mar 9;10:80. doi: 10.3389/fnins.2016.00080. eCollection 2016. PMID 27013943
• Frye RE, Sequeira JM, Quadros EV, James SJ, Rossignol DA. Cerebral folate receptor autoantibodies in autism spectrum disorder. Mol Psychiatry. 2013 Mar;18(3):369-81. doi: 10.1038/mp.2011.175. Epub 2012 Jan 10. PMID 22230883

Идентификаторы

NCT: NCT04060030 · AS Leucovorin

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗